Prognostic Factors Affecting Survival in Malignant Pleural Mesothelioma: Analysis of 125 Subjects

Aim of the Study Determining the pre-treatment prognostic factors in malignant pleural mesothelioma is important in terms of estimating the course of the disease and selecting patients who are candidate for multimodal therapy. The aim of the study was to determine the prognostic factors affecting survival in patients with malignant pleural mesothelioma. Study Design One hundred and twenty-five patients who had been diagnosed histologically as having malignant pleural mesothelioma over the past 5 years were evaluated retrospectively. Relationships of survival of the patients with their age, gender, exposure to asbestos, smoking history, platelet, hemoglobin, leukocyte (WBC) and serum LDH values, histology, performance score and stage of disease were examined. Results Advanced clinical stage, N2 nodal involvement and the presence of distant metastasis were found to be related to survival. Sarcomatous histology was found to be a poor prognostic factor independently of other factors. Conclusions We showed that histological subtype and stage of disease were the most important parameters in planning the treatment, especially in determining the patients who were candidate for multimodal treatment and in estimating the prognosis.

[1]  V. Rusch,et al.  Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Marinaccio,et al.  Effects of Combined Therapies on the Survival of Pleural Mesothelioma Patients Treated in Brescia, 1982–2006 , 2012, Tumori.

[3]  L. Garland Chemotherapy for Malignant Pleural Mesothelioma , 2011, Current treatment options in oncology.

[4]  M. Metintaş,et al.  Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  J. V. van Meerbeeck,et al.  A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. , 2009, European journal of cancer.

[6]  H. Dienemann,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[7]  M. Metintaş,et al.  A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience. , 2007, Lung cancer.

[8]  A. Davies,et al.  The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Uçgun,et al.  Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. , 2001, Respiratory medicine.

[11]  V. Roggli,et al.  Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases. , 2000, Environmental health perspectives.

[12]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[13]  V. Rusch,et al.  A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.

[14]  J. Peto,et al.  Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.

[15]  H. Hoogsteden,et al.  Prognostic factors and survival in malignant pleural mesothelioma. , 1994, The European respiratory journal.

[16]  R. Ginsberg,et al.  Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[18]  L. Norton,et al.  Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. , 1982, Annals of internal medicine.

[19]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  G. Hillerdal Staging and evaluating responses in malignant pleural mesothelioma. , 2004, Lung cancer.

[21]  P. Janne Chemotherapy for malignant pleural mesothelioma. , 2003, Clinical lung cancer.

[22]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[23]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. G. Butchart,et al.  Pleural mesothelioma. , 1990, Current opinion in oncology.

[25]  R. Shemin,et al.  Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. Selikoff,et al.  Occupational exposure to asbestos: population at risk and projected mortality--1980-2030. , 1982, American journal of industrial medicine.